2 completed, 1 active not recruiting, 1 terminated, 1 withdrawn. 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Rogaratinib: new trials by email Literature Review of Rogaratinib trials Research Report on Rogaratinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
Acrocephalosyndactylia (2) · Carcinoma, Transitional Cell (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Gastrointestinal Stromal Tumors (1) · Head and Neck Neoplasms (1) · Neoplasms (1) · Sarcoma (1) · Small Cell Lung Carcinoma (1) · Urinary Bladder Neoplasms (1)
Bayer (2) · Dana-Farber Cancer Institute (1) · National Cancer Institute (NCI) (1) · Swiss Cancer Institute (1)
Switzerland (3) · United States (2) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · China (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Germany (1) · Hong Kong (1) · Hungary (1) · Ireland (1)
Alfredo Addeo, MD (1) · Bradley A. McGregor, MD (1) · Suzanne George (1)
PMID 30807645, PMID 36240478, PMID 38573872, PMID 42191879
2016 (1), 2019 (1), UM1CA186709 (1)